Anti-EDG1 Polyclonal Antibody
Printable Datasheet
Image Preview (1 image)
.jpg)
|
Synonyms:
Sphingolipid Receptor 1, Endothelial Differentiation Gene 1, EDG1, S1PR1
Entrez Gene ID:
(Human) 1901
UniProt ID:
P21453
| Details | |
| Host / Isotype: | Rabbit |
| Class: | Polyclonal |
| Type: | Antibody |
| Species Reactivity: | Human (Hu) |
| Immunogen: | Synthetic peptide, KLH conjugated, corresponding to the C-terminal domain of human S1P1. |
| Ordering Information | ||||
| Pierce Anti-EDG1 Polyclonal Antibody | ||||
| Product Number | Pkg. Size | Price | Purchase | |
| OPA1-15004 | 25 µg | $453.00 | ||
| Storage: | -20º C, Avoid Freeze/Thaw Cycles |
| Form: | 25 µg of antibody (1mg/ml) in PBS, PH 7.7 containing 0.1% sodium azide. |
| Applications | Dilution |
| Immunohistochemistry (Paraffin) (IHC (P)) | Assay dependent |
| Western Blot (WB) | Assay dependent |
| Product Specific Information |
| OPA1-15004 detects S1P1 from human samples. OPA1-15004 has been successfully used in Western blotting and immunohistochemistry (paraffin) procedures. The OPA1-15004 immunogen is a synthetic peptide, KLH conjugated, corresponding to the C-terminal domain of human S1P1. Figure 1 illustrates immunohistochemical staining of S1P1 in human heart vessel tissue using OPA1-15004. |
| General Information |
| S1P1 transcripts have been reported to be present in embryonic and adult brain, lung alveolar macrophages, vascular smooth muscle cells, endothelial cells, fibroblasts, melanocytes, and TAg-Jurkat T cells, but to be absent from breast cancer cell lines. G-protein Coupled Receptors (GPCRs) comprise one of the largest families of signaling molecules with more than a thousand members currently predicted to exist. All GPCRs share a structural motif consisting of seven membrane-spanning helices, and exist in both active and inactive forms. An array of activating ligands participate in the conformation of GPCRs which S1P1 leads to signaling via G-proteins and downstream effectors. Ongoing studies have also shown the vast series of reactions which participate in the negative regulation of GPCRs. This "turn-off" activity has tremendous implications for the physiological action of the cell, and continues to drive pharmacological research for new drug candidates. Two blockbuster drugs which have been developed as GPCR-targeted pharmaceuticals are Zyprexa (Eli Lilly) and Claritin (Schering-Plough) which have multi-billion dollar shares of the mental health and allergy markets, respectively. |
|
Immunohistochemistry with anti-EDG1 Polyclonal Antibody (OPA1-15004)
|
(This product is for In Vitro experimental use only.)
 |
|||||||||||||
PO
Box 117, Rockford, IL 61105 USA |
 |
 |
